Diagnostic significance of combined detection of epstein-barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 5, 2014, Pages 2001-2006

  Cai, Yong Lin ^a   Li, Jun ^a   Lu, Ai Ying ^a   Zheng, Yu Ming ^a   Zhong, Wei Ming ^b   Wang, Wei ^c   Gao, Jian Quan ^b   Zeng, Hong ^a   Cheng, Ji Ru ^a   Tang, Min Zhong ^a,d  

^a Wuzhou Health System Key Laboratory for Nasopharyngeal Carcinoma Etiology and Molecular Mechanism   (China)

^b Wuzhou People's Hospital   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

^d BEIJING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Antibody; Epstein barr virus; Nasopharyngeal carcinoma; Serodiagnosis; Tumor marker

Indexed keywords

CAPSID PROTEIN; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; BLOOD; CASE CONTROL STUDY; CHINA; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CASE-CONTROL STUDIES; CHINA; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LOGISTIC MODELS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 84899125455     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.5.2001     Document Type: Article

References (33)

1. Bocian J, Januszkiewicz-Lewandowska D (2011). Epstein-Barr virus infection-life cycle, methods of diagnosis, associated diseases. Postepy Hig Med Dosw (Online), 65, 286-98.
2. Brennan B (2006). Nasopharyngeal carcinoma. Orphanet J Rare Dis, 1, 23.
3. Burgos JS (2005). Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Med Oncol, 22, 113-21.
4. Cai YL, Zheng YM, Wang W, et al (2010). Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma. Nan Fang Yi Ke Da Xue Xue Bao, 30, 2746-8.
5. Chen H, Luo YL, Zhang L, et al (2013). EA-D p45-IgG as a potential biomarker for nasopharyngeal carcinoma diagnosis. Asian Pac J Cancer Prev, 14, 7433-8.
6. Cheng WM, Chan KH, Chen HL, et al (2002). Assessing the risk of nasopharyngeal carcinoma on the basis of EBV antibody spectrum. Int J Cancer Suppl, 97, 489-92.
7. Chien YC, Chen JY, Liu MY, et al (2001). Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med, 345, 1877-82.
8. Deng H, Zeng Y, Lei Y, et al (1995). Serological survey of nasopharyngeal carcinoma in 21 cities of south China. Chin Med J, 108, 300-3.
9. Fachiroh J, Paramita DK, Hariwiyanto B, et al (2006). Singleassay combination of Epstein-Barr Virus (EBV) EBNA1-and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol, 44, 1459-67.
10. Feng P, Ren EC, Liu D, Chan SH, Hu H (2000). Expression of Epstein-Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis. J Gen Virol, 81, 2417-23.
11. Feng P, Chan SH, Soo MY, et al (2001). Antibody response to Epstein-Barr virus Rta protein in patients with nasopharyngeal carcinoma: a new serologic parameter for diagnosis. Cancer, 92, 1872-80.
12. Han BL, Xu XY, Zhang CZ, et al (2012). Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev, 13, 2577-81.
13. Hariwiyanto B, Sastrowiyoto S, Mubarika S, Salugu M (2010). LMP1 and LMP2 may be prognostic factors for outcome of therapy in nasopharyngeal cancers in Indonesia. Asian Pac J Cancer Prev, 11, 763-6.
14. Hu B, Hong G, Li Z, et al (2007). Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma. Appl Biochem Biotechnol, 47, 59-69.
15. Huang TR, Zhang SW, Chen WQ, et al (2012). Trends in nasopharyngeal carcinoma mortality in China, 1973-2005. Asian Pac J Cancer Prev, 13, 2495-502.
16. Jia WH, Huang QH, Liao J, et al (2006). Trends in incidence and mortality of nasopharyngeal carcinoma over a 20-25 year period (1978/1983-2002) in Sihui and Cangwu counties in southern China. BMC Cancer, 6, 178.
17. Leung SF, Tam JS, Chan AT, et al (2004). Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody. Clin Chem, 50, 339-45.
18. Li HF, Zhong JM, Liao J (2007). Detection of EB virus IgA/ VCA, IgA/EA and IgG/EA antibodies in nasopharyngeal carcinoma diagnosis. Guangxi Med J, 29, 500-1.
19. Liu P, Speck SH (2003). Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology, 310, 199-206.
20. Liu Y, Huang Q, Liu W, et al (2012). Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer Suppl, 131, 406-16.
21. Niedobitek G (2000). Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol, 53, 248-54.
22. Raab-Traub N (2002). Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol, 12, 431-41.
23. Ragoczy T, Heston L, Miller G (1998). The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol, 72, 7978-84.
24. Ren J, Zhang MX, Zhang GX, et al (2006). Studies on antibody response to recombinant Rta protein in patient with nasopharyngeal carcinoma. Chin J Microbiol Immunol, 26, 1057-9.
25. Tang M, Zeng Y, Poisson A, et al (2010). Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. Genes Immun, 11, 334-42.
26. Tang M, Lautenberger JA, Gao X, et al (2012). The principal genetic determinants for nasopharyngeal carcinoma in china involve the hla class i antigen recognition groove. PLoS Genet, 8, 1003103.
27. Tao Q, Srivastava G, Chan AC, et al (1995). Evidence for lytic infection by Epstein-Barr virus in mucosal lymphocytes instead of nasopharyngeal epithelial cells in normal individuals. J Med Virol, 45, 71-7.
28. Walling DM, Flaitz CM, Nichols CM, Hudnall SD, Adler-Storthz K (2001). Persistent productive Epstein-Barr virus replication in normal epithelial cells in vivo. J Infect Dis, 184, 1499-507.
29. Wen S, Mizugaki Y, Shinozaki F, Takada K (1997). Epstein-Barr virus (EBV) infection in salivary gland tumors: lytic EBV infection in nonmalignant epithelial cells surrounded by EBV-positive T-lymphoma cells. Virology, 227, 484-7.
30. Xue SA, Lu QL, Poulsom R, et al (2000). Expression of two related viral early genes in Epstein-Barr virus-associated tumors. J Virol, 74, 2793-803.
31. Yu KJ, Hsu WL, Pfeiffer RM, et al (2011). Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res, 17, 1906-14.
32. Zhan SB, Zhong JM, Mai ZP, et al (2009). Improve on serological diagnosis method of nasopharyngeal carcinoma. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, 23, 65-7.
33. Zhang JX, Chen HL, Zong YS, et al (1998). Epstein-Barr virus expression within keratinizing nasopharyngeal carcinoma. J Med Virol, 55, 227-33.